| Poly (amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines M Skwarczynski, G Zhao, JC Boer, V Ozberk, A Azuar, JG Cruz, ... Science advances 6 (5), eaax2285, 2020 | 94 | 2020 |
| Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial S Sekuloski, MR Batzloff, P Griffin, W Parsonage, S Elliott, J Hartas, ... PLoS One 13 (7), e0198658, 2018 | 81 | 2018 |
| Current approaches to group A streptococcal vaccine development JB Dale, MR Batzloff, PP Cleary, HS Courtney, MF Good, G Grandi, ... | 68 | 2016 |
| A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia M Pandey, E Langshaw, J Hartas, A Lam, MR Batzloff, MF Good The Journal of Immunology 194 (12), 5915-5925, 2015 | 62 | 2015 |
| Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help M Pandey, MN Wykes, J Hartas, MF Good, MR Batzloff The Journal of Immunology 190 (6), 2692-2701, 2013 | 60 | 2013 |
| Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models T Rivera-Hernandez, M Pandey, A Henningham, J Cole, B Choudhury, ... MBio 7 (3), 10.1128/mbio. 00618-16, 2016 | 56 | 2016 |
| Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection M Pandey, MR Batzloff, MF Good PloS one 4 (4), e5147, 2009 | 56 | 2009 |
| Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines PM Moyle, C Olive, MF Ho, M Pandey, J Dyer, A Suhrbier, Y Fujita, I Toth Journal of medicinal chemistry 50 (19), 4721-4727, 2007 | 52 | 2007 |
| Rheumatic heart disease: a review of the current status of global research activity LM Dooley, TB Ahmad, M Pandey, MF Good, M Kotiw Autoimmunity reviews 20 (2), 102740, 2021 | 50 | 2021 |
| Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR/S mutant streptococci M Pandey, R Mortensen, A Calcutt, J Powell, MR Batzloff, J Dietrich, ... The Journal of Immunology 196 (8), 3364-3374, 2016 | 46 | 2016 |
| Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci MF Good, M Pandey, MR Batzloff, GJ Tyrrell Expert review of vaccines 14 (11), 1459-1470, 2015 | 46 | 2015 |
| Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): establishing a group A Streptococcus pharyngitis human infection study J Osowicki, KI Azzopardi, C Baker, CS Waddington, M Pandey, T Schuster, ... Vaccine 37 (26), 3485-3494, 2019 | 45 | 2019 |
| A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study J Osowicki, KI Azzopardi, L Fabri, HR Frost, T Rivera-Hernandez, ... The Lancet Microbe 2 (7), e291-e299, 2021 | 43 | 2021 |
| Streptococcal immunity is constrained by lack of immunological memory following a single episode of pyoderma M Pandey, V Ozberk, A Calcutt, E Langshaw, J Powell, ... PLoS pathogens 12 (12), e1006122, 2016 | 39 | 2016 |
| Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a … M Kotiw, M Johnson, M Pandey, S Fry, SL Hazell, HJ Netter, MF Good, ... Clinical and Vaccine Immunology 19 (2), 268-276, 2012 | 37 | 2012 |
| Novel platform technology for modular mucosal vaccine that protects against streptococcus M Zaman, V Ozberk, EL Langshaw, V McPhun, JL Powell, ZN Phillips, ... Scientific reports 6 (1), 39274, 2016 | 35 | 2016 |
| Strategies in the development of vaccines to prevent infections with group A streptococcus MF Good, M Batzloff, M Pandey Human vaccines & immunotherapeutics 9 (11), 2393-2397, 2013 | 33 | 2013 |
| Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial M Pandey, J Powell, A Calcutt, M Zaman, ZN Phillips, MF Ho, MR Batzloff, ... Scientific reports 7 (1), 13786, 2017 | 30 | 2017 |
| Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease MR Batzloff, M Pandey, C Olive, MF Good Immunologic research 35, 233-248, 2006 | 28 | 2006 |
| Vaccination against rheumatic heart disease: a review of current research strategies and challenges M Pandey, MR Batzloff, MF Good Current infectious disease reports 14, 381-390, 2012 | 25 | 2012 |
